Do you typically recommend avoiding neupogen during radiation treatments?  

It depends on the reason and expected benefit. If myelosuppression is holding up RT for cervical cancer patients, then I would not hesitate to give neupogen to avoid or minimize a treatment break. There would be more benefit to neupogen and continuing RT than a downside. Usually, I would try to giv...

Generally speaking, it is our institutional practice to not hold RT for neupogen/neulasta administration. The only times we would consider is if the patient has a concurrent neutropenic fever.  The history behind holding RT during neupogen administration originated in the era of 3D techniques....

This myth that growth factors cannot be safely combined with RT was tested in the 2D era by a protocol done at the JCRT adding etanidazole to chemoradiotherapy for patients with esophageal cancer. We gave patients G-CSF during the weeks they did not receive chemotherapy. This was effective in keepin...

I am still reluctant to add growth factor support during thoracic radiation. Dr. Lilenbaum published in the Journal of Thoracic Oncology in 2010 a phase II trial incorporating colony-stimulating factors to platinum etoposide thoracic radiation with consolidation docetaxel. 26% of patients had grade ...

To revive an old question! Has anyone's practice changed since the publication of the subset analysis evaluating the use of G-CSF in the phase 3 CONVERT trial (Gomes et al., PMID 33545577)? There appeared to be no difference in radiation-related toxicity, mortality, or survival whether or not patien...

I agree that we don't hold RT if the patient has been given Neupogen/Neulasta but I encourage the medical oncologists not to give it for the reasons given by @Elizabeth M. Nichols. When the neutrophil count falls below 500, I will recheck the WBC in 2-3 days and continue radiation as long as the neu...